This CPB has been revised to: (1) extend approval duration for treatment-resistant depression (TRD) to 6 months (from 3 months) for continuation of esketamine (Spravato) therapy, and (ii) add serotonin modulators as an additional class of antidepressant that can be trialed for TRD.